Acadia is spending a small fortune on NNZ2566 so you would think they are keeping a very close eye on the development of NNZ 2591.
Acadia won’t necessarily spend “a small fortune” on trofinetide. Acadia’s committed spend is really just ~US$65m – the $10m upfront and $55m Phase 3 Rett costs. In the world of pharma, US$55m to take a drug through Phase 3 is an exceedingly modest outlay.
If Phase 3 comes up roses (or if the scent of rose can be smelt downwind) Acadia will spend considerably more, either per the licensing agreement and/or through acquisition.
I agree that Acadia will be keeping a close eye on the development of NNZ-2591. My concern is that, with some clever manoeuvring, Acadia could clip NNZ-2591 and add it to the bouquet for nix.
NEU Price at posting:
$1.67 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)